Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

Philip A. Philip, Michelle R. Mahoney, Kyle D. Holen, Donald W Northfelt, Henry Clement Pitot, Joel Picus, Patrick J. Flynn, Charles Erlichman

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

BACKGROUND: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are rational targets for therapy in hepatocellular cancer (HCC). METHODS: Patients with histologically proven HCC and not amenable to curative or liver directed therapy were included in this 2-stage phase 2 trial. Eligibility included an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and Child's Pugh score of A or B, and 1 prior systemic therapy. Patients received erlotinib 150 mg daily and bevacizumab 10 mg/kg on days 1 and 15 every 28 days. Objective tumor response was the primary end point. RESULTS: Twenty-seven patients with advanced HCC (median age, 60 years) were enrolled in this multi-institutional study. The proportion of patients with Child's A classification was 74%. One patient had a confirmed partial response and 11 (48%) achieved stable disease. Median time to disease progression was 3.0 months (95% confidence interval [CI], 1.8-7.1). Median survival time was 9.5 months (95% CI, 7.1-17.1). Grade 3 toxicities included rash, hypertension, fatigue, and diarrhea. CONCLUSIONS: In this trial, erlotinib combined with bevacizumab had minimal activity in patients with advanced HCC based on objective response and progression-free survival. The role of targeting EGFR and VEGF in HCC needs further evaluation in molecularly selected patients.

Original languageEnglish (US)
Pages (from-to)2424-2430
Number of pages7
JournalCancer
Volume118
Issue number9
DOIs
StatePublished - May 1 2012

Fingerprint

Liver Neoplasms
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Confidence Intervals
Erlotinib Hydrochloride
Bevacizumab
Exanthema
Disease-Free Survival
Fatigue
Disease Progression
Diarrhea
Therapeutics
Hypertension
Survival
Liver
Neoplasms

Keywords

  • bevacizumab
  • epidermal growth factor receptor
  • erlotinib
  • hepatocellular cancer
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. / Philip, Philip A.; Mahoney, Michelle R.; Holen, Kyle D.; Northfelt, Donald W; Pitot, Henry Clement; Picus, Joel; Flynn, Patrick J.; Erlichman, Charles.

In: Cancer, Vol. 118, No. 9, 01.05.2012, p. 2424-2430.

Research output: Contribution to journalArticle

Philip, PA, Mahoney, MR, Holen, KD, Northfelt, DW, Pitot, HC, Picus, J, Flynn, PJ & Erlichman, C 2012, 'Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer', Cancer, vol. 118, no. 9, pp. 2424-2430. https://doi.org/10.1002/cncr.26556
Philip, Philip A. ; Mahoney, Michelle R. ; Holen, Kyle D. ; Northfelt, Donald W ; Pitot, Henry Clement ; Picus, Joel ; Flynn, Patrick J. ; Erlichman, Charles. / Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. In: Cancer. 2012 ; Vol. 118, No. 9. pp. 2424-2430.
@article{3fcb1568296344798cc3e11df08ef1fb,
title = "Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer",
abstract = "BACKGROUND: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are rational targets for therapy in hepatocellular cancer (HCC). METHODS: Patients with histologically proven HCC and not amenable to curative or liver directed therapy were included in this 2-stage phase 2 trial. Eligibility included an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and Child's Pugh score of A or B, and 1 prior systemic therapy. Patients received erlotinib 150 mg daily and bevacizumab 10 mg/kg on days 1 and 15 every 28 days. Objective tumor response was the primary end point. RESULTS: Twenty-seven patients with advanced HCC (median age, 60 years) were enrolled in this multi-institutional study. The proportion of patients with Child's A classification was 74{\%}. One patient had a confirmed partial response and 11 (48{\%}) achieved stable disease. Median time to disease progression was 3.0 months (95{\%} confidence interval [CI], 1.8-7.1). Median survival time was 9.5 months (95{\%} CI, 7.1-17.1). Grade 3 toxicities included rash, hypertension, fatigue, and diarrhea. CONCLUSIONS: In this trial, erlotinib combined with bevacizumab had minimal activity in patients with advanced HCC based on objective response and progression-free survival. The role of targeting EGFR and VEGF in HCC needs further evaluation in molecularly selected patients.",
keywords = "bevacizumab, epidermal growth factor receptor, erlotinib, hepatocellular cancer, vascular endothelial growth factor",
author = "Philip, {Philip A.} and Mahoney, {Michelle R.} and Holen, {Kyle D.} and Northfelt, {Donald W} and Pitot, {Henry Clement} and Joel Picus and Flynn, {Patrick J.} and Charles Erlichman",
year = "2012",
month = "5",
day = "1",
doi = "10.1002/cncr.26556",
language = "English (US)",
volume = "118",
pages = "2424--2430",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

AU - Philip, Philip A.

AU - Mahoney, Michelle R.

AU - Holen, Kyle D.

AU - Northfelt, Donald W

AU - Pitot, Henry Clement

AU - Picus, Joel

AU - Flynn, Patrick J.

AU - Erlichman, Charles

PY - 2012/5/1

Y1 - 2012/5/1

N2 - BACKGROUND: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are rational targets for therapy in hepatocellular cancer (HCC). METHODS: Patients with histologically proven HCC and not amenable to curative or liver directed therapy were included in this 2-stage phase 2 trial. Eligibility included an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and Child's Pugh score of A or B, and 1 prior systemic therapy. Patients received erlotinib 150 mg daily and bevacizumab 10 mg/kg on days 1 and 15 every 28 days. Objective tumor response was the primary end point. RESULTS: Twenty-seven patients with advanced HCC (median age, 60 years) were enrolled in this multi-institutional study. The proportion of patients with Child's A classification was 74%. One patient had a confirmed partial response and 11 (48%) achieved stable disease. Median time to disease progression was 3.0 months (95% confidence interval [CI], 1.8-7.1). Median survival time was 9.5 months (95% CI, 7.1-17.1). Grade 3 toxicities included rash, hypertension, fatigue, and diarrhea. CONCLUSIONS: In this trial, erlotinib combined with bevacizumab had minimal activity in patients with advanced HCC based on objective response and progression-free survival. The role of targeting EGFR and VEGF in HCC needs further evaluation in molecularly selected patients.

AB - BACKGROUND: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are rational targets for therapy in hepatocellular cancer (HCC). METHODS: Patients with histologically proven HCC and not amenable to curative or liver directed therapy were included in this 2-stage phase 2 trial. Eligibility included an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and Child's Pugh score of A or B, and 1 prior systemic therapy. Patients received erlotinib 150 mg daily and bevacizumab 10 mg/kg on days 1 and 15 every 28 days. Objective tumor response was the primary end point. RESULTS: Twenty-seven patients with advanced HCC (median age, 60 years) were enrolled in this multi-institutional study. The proportion of patients with Child's A classification was 74%. One patient had a confirmed partial response and 11 (48%) achieved stable disease. Median time to disease progression was 3.0 months (95% confidence interval [CI], 1.8-7.1). Median survival time was 9.5 months (95% CI, 7.1-17.1). Grade 3 toxicities included rash, hypertension, fatigue, and diarrhea. CONCLUSIONS: In this trial, erlotinib combined with bevacizumab had minimal activity in patients with advanced HCC based on objective response and progression-free survival. The role of targeting EGFR and VEGF in HCC needs further evaluation in molecularly selected patients.

KW - bevacizumab

KW - epidermal growth factor receptor

KW - erlotinib

KW - hepatocellular cancer

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84860224913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860224913&partnerID=8YFLogxK

U2 - 10.1002/cncr.26556

DO - 10.1002/cncr.26556

M3 - Article

C2 - 21953248

AN - SCOPUS:84860224913

VL - 118

SP - 2424

EP - 2430

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -